{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:23:34Z","timestamp":1793197414884,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"15","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2026,4,28]]},"DOI":"10.1038\/s41388-026-03728-6","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T05:48:48Z","timestamp":1774331328000},"page":"1338-1356","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["TRIM21-mediated degradation of HILPDA overcomes anti-PD-1 immunotherapy resistance in breast cancer by limiting PD-L1 palmitoylation"],"prefix":"10.1038","volume":"45","author":[{"given":"Xi","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaming","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baiyang","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2064-9948","authenticated-orcid":false,"given":"Jianjiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7461-8853","authenticated-orcid":false,"given":"Jianguo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5639-8463","authenticated-orcid":false,"given":"Xi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"3728_CR1","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1093\/annonc\/mdz011","volume":"30","author":"O Hamid","year":"2019","unstructured":"Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019;30:582\u20138.","journal-title":"Ann Oncol"},{"key":"3728_CR2","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018\u201328.","journal-title":"N Engl J Med"},{"key":"3728_CR3","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/annonc\/mdy518","volume":"30","author":"S Adams","year":"2019","unstructured":"Adams S, Loi S, Toppmeyer D, Cescon DW, De Laurentiis M, Nanda R, et al. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. Ann Oncol. 2019;30:405\u201311.","journal-title":"Ann Oncol"},{"key":"3728_CR4","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet. 2017;389:2492\u2013502.","journal-title":"Lancet"},{"key":"3728_CR5","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","volume":"13","author":"G Bianchini","year":"2016","unstructured":"Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13:674\u201390.","journal-title":"Nat Rev Clin Oncol"},{"key":"3728_CR6","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","volume":"19","author":"G Bianchini","year":"2022","unstructured":"Bianchini G, De Angelis C, Licata L, Gianni L. Treatment landscape of triple-negative breast cancer - expanded options, evolving needs. Nat Rev Clin Oncol. 2022;19:91\u2013113.","journal-title":"Nat Rev Clin Oncol"},{"key":"3728_CR7","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ccell.2023.12.013","volume":"42","author":"D Memon","year":"2024","unstructured":"Memon D, Schoenfeld AJ, Ye D, Fromm G, Rizvi H, Zhang X, et al. Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer. Cancer Cell. 2024;42:209\u201324.e209.","journal-title":"Cancer Cell"},{"key":"3728_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-1144-6","volume":"19","author":"D Ren","year":"2020","unstructured":"Ren D, Hua Y, Yu B, Ye X, He Z, Li C, et al. Predictive biomarkers and mechanisms underlying resistance to PD1\/PD-L1 blockade cancer immunotherapy. Mol Cancer. 2020;19:19.","journal-title":"Mol Cancer"},{"key":"3728_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2022.100907","volume":"66","author":"K Pang","year":"2023","unstructured":"Pang K, Shi ZD, Wei LY, Dong Y, Ma YY, Wang W, et al. Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1\/PD-L1 blockade. Drug Resist Updat. 2023;66:100907.","journal-title":"Drug Resist Updat"},{"key":"3728_CR10","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41392-018-0022-9","volume":"3","author":"D Escors","year":"2018","unstructured":"Escors D, Gato-Canas M, Zuazo M, Arasanz H, Garcia-Granda MJ, Vera R, et al. The intracellular signalosome of PD-L1 in cancer cells. Signal Transduct Target Ther. 2018;3:26.","journal-title":"Signal Transduct Target Ther"},{"key":"3728_CR11","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s13046-019-1161-8","volume":"38","author":"M Shen","year":"2019","unstructured":"Shen M, Xu Z, Xu W, Jiang K, Zhang F, Ding Q, et al. Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK\/STAT3\/PD-L1 pathway. J Exp Clin Cancer Res. 2019;38:149.","journal-title":"J Exp Clin Cancer Res"},{"key":"3728_CR12","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nature23669","volume":"549","author":"R Mezzadra","year":"2017","unstructured":"Mezzadra R, Sun C, Jae LT, Gomez-Eerland R, de Vries E, Wu W, et al. Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. Nature. 2017;549:106\u201310.","journal-title":"Nature"},{"key":"3728_CR13","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ccell.2019.06.008","volume":"36","author":"HH Lee","year":"2019","unstructured":"Lee HH, Wang YN, Xia W, Chen CH, Rau KM, Ye L, et al. Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1\/PD-L1 Therapeutic Efficacy. Cancer Cell. 2019;36:168\u201378.e164.","journal-title":"Cancer Cell"},{"key":"3728_CR14","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/s41392-025-02171-5","volume":"10","author":"Y Liu","year":"2025","unstructured":"Liu Y, Liu Y, Niu X, Chen A, Li Y, Yu Y, et al. Massively parallel interrogation of human functional variants modulating cancer immunosurveillance. Signal Transduct Target Ther. 2025;10:88.","journal-title":"Signal Transduct Target Ther"},{"key":"3728_CR15","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1158\/2326-6066.CIR-24-0649","volume":"13","author":"MD Galsky","year":"2025","unstructured":"Galsky MD, Kockx M, Roels J, Van Elzen R, Guan X, Yuen K, et al. Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer. Cancer Immunol Res. 2025;13:476\u201386.","journal-title":"Cancer Immunol Res"},{"key":"3728_CR16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41422-018-0124-5","volume":"29","author":"Y Yang","year":"2019","unstructured":"Yang Y, Hsu JM, Sun L, Chan LC, Li CW, Hsu JL, et al. Palmitoylation stabilizes PD-L1 to promote breast tumor growth. Cell Res. 2019;29:83\u20136.","journal-title":"Cell Res"},{"key":"3728_CR17","doi-asserted-by":"crossref","unstructured":"Konen JM, Rodriguez BL, Fradette JJ, Gibson L, Davis D, Minelli R et al. Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras\/p53 Mutant Lung Cancer. Cancers 2019; 11.","DOI":"10.3390\/cancers11040462"},{"key":"3728_CR18","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.2147\/OTT.S187280","volume":"12","author":"W Xue","year":"2019","unstructured":"Xue W, Li W, Zhang T, Li Z, Wang Y, Qiu Y, et al. Anti-PD1 up-regulates PD-L1 expression and inhibits T-cell lymphoma progression: possible involvement of an IFN-gamma-associated JAK-STAT pathway. Onco Targets Ther. 2019;12:2079\u201388.","journal-title":"Onco Targets Ther"},{"key":"3728_CR19","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41421-022-00507-x","volume":"9","author":"Y Wang","year":"2023","unstructured":"Wang Y, Jia Z, Liang C, He Y, Cong M, Wu Q, et al. MTSS1 curtails lung adenocarcinoma immune evasion by promoting AIP4-mediated PD-L1 monoubiquitination and lysosomal degradation. Cell Discov. 2023;9:20.","journal-title":"Cell Discov"},{"key":"3728_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216861","volume":"590","author":"L Wang","year":"2024","unstructured":"Wang L, Liu X, Han Y, Tsai HI, Dan Z, Yang P, et al. TRAF6 enhances PD-L1 expression through YAP1-TFCP2 signaling in melanoma. Cancer Lett. 2024;590:216861.","journal-title":"Cancer Lett"},{"key":"3728_CR21","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.ccell.2017.08.004","volume":"32","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Kurupati R, Liu L, Zhou XY, Zhang G, Hudaihed A, et al. Enhancing CD8(+) T Cell Fatty Acid Catabolism within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy. Cancer Cell. 2017;32:377\u201391.e379.","journal-title":"Cancer Cell"},{"key":"3728_CR22","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/s41586-024-07787-1","volume":"633","author":"M Soula","year":"2024","unstructured":"Soula M, Unlu G, Welch R, Chudnovskiy A, Uygur B, Shah V, et al. Glycosphingolipid synthesis mediates immune evasion in KRAS-driven cancer. Nature. 2024;633:451\u20138.","journal-title":"Nature"},{"key":"3728_CR23","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/s41588-025-02077-6","volume":"57","author":"L Liang","year":"2025","unstructured":"Liang L, Kuang X, He Y, Zhu L, Lau P, Li X, et al. Alterations in PD-L1 succinylation shape anti-tumor immune responses in melanoma. Nat Genet. 2025;57:680\u201393.","journal-title":"Nat Genet"},{"key":"3728_CR24","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41392-020-0117-y","volume":"5","author":"D Zhang","year":"2020","unstructured":"Zhang D, Shi R, Xiang W, Kang X, Tang B, Li C, et al. The Agpat4\/LPA axis in colorectal cancer cells regulates antitumor responses via p38\/p65 signaling in macrophages. Signal Transduct Target Ther. 2020;5:24.","journal-title":"Signal Transduct Target Ther"},{"key":"3728_CR25","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1016\/j.cell.2020.11.039","volume":"183","author":"JH Goodman","year":"2020","unstructured":"Goodman JH, Ferrante AW Jr. Fighting for Fat: Gluttonous Tumors and Starved T Cells. Cell. 2020;183:1739\u201341.","journal-title":"Cell"},{"key":"3728_CR26","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jare.2024.02.009","volume":"68","author":"N Shao","year":"2025","unstructured":"Shao N, Qiu H, Liu J, Xiao D, Zhao J, Chen C, et al. Targeting lipid metabolism of macrophages: A new strategy for tumor therapy. J Adv Res. 2025;68:99\u2013114.","journal-title":"J Adv Res"},{"key":"3728_CR27","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41551-019-0375-6","volume":"3","author":"H Yao","year":"2019","unstructured":"Yao H, Lan J, Li C, Shi H, Brosseau JP, Wang H, et al. Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours. Nat Biomed Eng. 2019;3:306\u201317.","journal-title":"Nat Biomed Eng"},{"key":"3728_CR28","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.jhep.2023.03.041","volume":"79","author":"D Povero","year":"2023","unstructured":"Povero D, Chen Y, Johnson SM, McMahon CE, Pan M, Bao H, et al. HILPDA promotes NASH-driven HCC development by restraining intracellular fatty acid flux in hypoxia. J Hepatol. 2023;79:378\u201393.","journal-title":"J Hepatol"},{"key":"3728_CR29","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.canlet.2020.06.013","volume":"493","author":"D Povero","year":"2020","unstructured":"Povero D, Johnson SM, Liu J. Hypoxia, hypoxia-inducible gene 2 (HIG2)\/HILPDA, and intracellular lipolysis in cancer. Cancer Lett. 2020;493:71\u20139.","journal-title":"Cancer Lett"},{"key":"3728_CR30","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/j.celrep.2020.01.046","volume":"30","author":"X van Dierendonck","year":"2020","unstructured":"van Dierendonck X, de la Rosa Rodriguez MA, Georgiadi A, Mattijssen F, Dijk W, van Weeghel M, et al. HILPDA Uncouples Lipid Droplet Accumulation in Adipose Tissue Macrophages from Inflammation and Metabolic Dysregulation. Cell Rep. 2020;30:1811\u201322.e1816.","journal-title":"Cell Rep"},{"key":"3728_CR31","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2114739119","volume":"119","author":"X van Dierendonck","year":"2022","unstructured":"van Dierendonck X, Vrieling F, Smeehuijzen L, Deng L, Boogaard JP, Croes CA, et al. Triglyceride breakdown from lipid droplets regulates the inflammatory response in macrophages. Proc Natl Acad Sci USA 2022;119:e2114739119.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3728_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2023.101773","volume":"75","author":"L Deng","year":"2023","unstructured":"Deng L, Wu SA, Qi L, Kersten S. HILPDA is a lipotoxic marker in adipocytes that mediates the autocrine negative feedback regulation of triglyceride hydrolysis by fatty acids and alleviates cellular lipotoxic stress. Mol Metab. 2023;75:101773.","journal-title":"Mol Metab"},{"key":"3728_CR33","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1016\/j.cmet.2022.11.003","volume":"34","author":"Z Gong","year":"2022","unstructured":"Gong Z, Li Q, Shi J, Liu ET, Shultz LD, Ren G. Lipid-laden lung mesenchymal cells foster breast cancer metastasis via metabolic reprogramming of tumor cells and natural killer cells. Cell Metab. 2022;34:1960\u201376.e1969.","journal-title":"Cell Metab"},{"key":"3728_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09277-9","volume":"10","author":"Y Zou","year":"2019","unstructured":"Zou Y, Palte MJ, Deik AA, Li H, Eaton JK, Wang W, et al. A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis. Nat Commun. 2019;10:1617.","journal-title":"Nat Commun"},{"key":"3728_CR35","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.canlet.2013.07.028","volume":"341","author":"SH Kim","year":"2013","unstructured":"Kim SH, Wang D, Park YY, Katoh H, Margalit O, Sheffer M, et al. HIG2 promotes colorectal cancer progression via hypoxia-dependent and independent pathways. Cancer Lett. 2013;341:159\u201365.","journal-title":"Cancer Lett"},{"key":"3728_CR36","doi-asserted-by":"publisher","first-page":"21.","DOI":"10.3892\/or.2021.7972","volume":"45","author":"JJ Grachan","year":"2021","unstructured":"Grachan JJ, Kery M, Giaccia AJ, Denko NC, Papandreou I. Lipid droplet storage promotes murine pancreatic tumor growth. Oncol Rep. 2021;45:21.","journal-title":"Oncol Rep"},{"key":"3728_CR37","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s12276-024-01180-8","volume":"56","author":"T Bae","year":"2024","unstructured":"Bae T, Hallis SP, Kwak MK. Hypoxia, oxidative stress, and the interplay of HIFs and NRF2 signaling in cancer. Exp Mol Med. 2024;56:501\u201314.","journal-title":"Exp Mol Med"},{"key":"3728_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2024.167576","volume":"1871","author":"M Cortini","year":"2025","unstructured":"Cortini M, Ilieva E, Massari S, Bettini G, Avnet S, Baldini N. Uncovering the protective role of lipid droplet accumulation against acid-induced oxidative stress and cell death in osteosarcoma. Biochim Biophys Acta Mol Basis Dis. 2025;1871:167576.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"3728_CR39","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","volume":"171","author":"N Riaz","year":"2017","unstructured":"Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS, et al. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell. 2017;171:934\u201349.e916.","journal-title":"Cell"},{"key":"3728_CR40","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","volume":"165","author":"W Hugo","year":"2016","unstructured":"Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell. 2016;165:35\u201344.","journal-title":"Cell"},{"key":"3728_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-015-0550-y","volume":"17","author":"P Jezequel","year":"2015","unstructured":"Jezequel P, Loussouarn D, Guerin-Charbonnel C, Campion L, Vanier A, Gouraud W, et al. Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response. Breast Cancer Res. 2015;17:43.","journal-title":"Breast Cancer Res"},{"key":"3728_CR42","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1158\/0008-5472.CAN-17-0307","volume":"77","author":"T Li","year":"2017","unstructured":"Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, et al. TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res. 2017;77:e108\u2013e110.","journal-title":"Cancer Res"},{"key":"3728_CR43","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","volume":"24","author":"P Jiang","year":"2018","unstructured":"Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24:1550\u20138.","journal-title":"Nat Med"},{"key":"3728_CR44","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2310479121","volume":"121","author":"L Sainero-Alcolado","year":"2024","unstructured":"Sainero-Alcolado L, Garde-Lapido E, Snaebjornsson MT, Schoch S, Stevens I, Ruiz-Perez MV, et al. Targeting MYC induces lipid droplet accumulation by upregulation of HILPDA in clear cell renal cell carcinoma. Proc Natl Acad Sci USA 2024;121:e2310479121.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3728_CR45","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1158\/2326-6066.CIR-22-0953","volume":"11","author":"EY Lemma","year":"2023","unstructured":"Lemma EY, Letian A, Altorki NK, McGraw TE. Regulation of PD-L1 Trafficking from Synthesis to Degradation. Cancer Immunol Res. 2023;11:866\u201374.","journal-title":"Cancer Immunol Res"},{"key":"3728_CR46","doi-asserted-by":"publisher","first-page":"bbab574.","DOI":"10.1093\/bib\/bbab574","volume":"23","author":"C Wang","year":"2022","unstructured":"Wang C, Tan X, Tang D, Gou Y, Han C, Ning W. GPS-Uber: a hybrid-learning framework for prediction of general and E3-specific lysine ubiquitination sites. Brief Bioinform. 2022;23:bbab574.","journal-title":"Brief Bioinform"},{"key":"3728_CR47","doi-asserted-by":"publisher","DOI":"10.1002\/ccs3.12041","volume":"18","author":"M Ye","year":"2024","unstructured":"Ye M, Xu L, Lu F, Chen L, Hu C, Chen J, et al. Hypoxia drives CBR4 down-regulation promotes gastroenteropancreatic neuroendocrine tumors via activation mammalian target of rapamycin mediated by fatty acid synthase. J Cell Commun Signal. 2024;18:e12041.","journal-title":"J Cell Commun Signal"},{"key":"3728_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2025.103543","volume":"81","author":"Q Shi","year":"2025","unstructured":"Shi Q, Liu Y, Yang W, Li Y, Wang C, Gao K. The covalent modification of STAT1 cysteines by sulforaphane promotes antitumor immunity via blocking IFN-gamma-induced PD-L1 expression. Redox Biol. 2025;81:103543.","journal-title":"Redox Biol"},{"key":"3728_CR49","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abj1640","volume":"7","author":"S Foss","year":"2022","unstructured":"Foss S, Jonsson A, Bottermann M, Watkinson R, Lode HE, McAdam MB, et al. Potent TRIM21 and complement-dependent intracellular antiviral immunity requires the IgG3 hinge. Sci Immunol. 2022;7:eabj1640.","journal-title":"Sci Immunol"},{"key":"3728_CR50","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/s41392-023-01450-3","volume":"8","author":"X Ma","year":"2023","unstructured":"Ma X, Jia S, Wang G, Liang M, Guo T, Du H, et al. TRIM28 promotes the escape of gastric cancer cells from immune surveillance by increasing PD-L1 abundance. Signal Transduct Target Ther. 2023;8:246.","journal-title":"Signal Transduct Target Ther"},{"key":"3728_CR51","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202304342","volume":"11","author":"N Wang","year":"2024","unstructured":"Wang N, Jiang Y, Li M, Wang H, Pan J, Tang Y, et al. Protein Kinase STK24 Promotes Tumor Immune Evasion via the AKT-PD-L1 Axis. Adv Sci. 2024;11:e2304342.","journal-title":"Adv Sci"},{"key":"3728_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101357","volume":"5","author":"Q Wang","year":"2024","unstructured":"Wang Q, Wang J, Yu D, Zhang Q, Hu H, Xu M, et al. Benzosceptrin C induces lysosomal degradation of PD-L1 and promotes antitumor immunity by targeting DHHC3. Cell Rep Med. 2024;5:101357.","journal-title":"Cell Rep Med"},{"key":"3728_CR53","doi-asserted-by":"publisher","DOI":"10.1002\/smtd.202301142","volume":"8","author":"Y Huang","year":"2024","unstructured":"Huang Y, Gao X, He QY, Liu W. A Interacting Model: How TRIM21 Orchestrates with Proteins in Intracellular Immunity. Small Methods. 2024;8:e2301142.","journal-title":"Small Methods"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03728-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03728-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03728-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T22:01:47Z","timestamp":1775512907000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03728-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":53,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2026,4,28]]}},"alternative-id":["3728"],"URL":"https:\/\/doi.org\/10.1038\/s41388-026-03728-6","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"17 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was conducted with human participants\/animal subjects and adhered strictly to the ethical standards set by the Second Affiliated Hospital of Harbin Medical University\u2019s Ethical Review Board. All procedures involving human participants complied with the ethical standards of the institutional and national research committee, in alignment with the 1964 Helsinki declaration and its later amendments, or comparable ethical standards for research involving human subjects. For research involving animal subjects, all procedures conformed to the international, national, and institutional guidelines for the care and use of animals. Informed consent was obtained from all individual participants included in the study. For animal studies, all necessary measures were taken to minimize pain and discomfort. This study received ethical approval from the Ethical Review Board of the Second Affiliated Hospital of Harbin Medical University, with the approval number YJSDW2022-277 and YJSKY2022-595.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}